{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:43Z","timestamp":1793766463121,"version":"4.6.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["BMU2025YFJHPY015"],"award-info":[{"award-number":["BMU2025YFJHPY015"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173216"],"award-info":[{"award-number":["82173216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972379"],"award-info":[{"award-number":["81972379"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872083"],"award-info":[{"award-number":["81872083"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2024IR30"],"award-info":[{"award-number":["2024IR30"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M750127"],"award-info":[{"award-number":["2024M750127"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102651","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:22:33Z","timestamp":1787066553000},"page":"102651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-6978","authenticated-orcid":false,"given":"Mingrui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10437","key":"10.1016\/j.clgc.2026.102651_bib0001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clgc.2026.102651_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2015.6036","article-title":"Trends in management for patients with localized prostate cancer, 1990-2013","volume":"314","author":"Cooperberg","year":"2015","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.clgc.2026.102651_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737140.2017.1333903","article-title":"Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment","volume":"17","author":"Anantharaman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"10.1016\/j.clgc.2026.102651_bib0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part B: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102651_bib0007","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2026.102651_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing","volume":"121","author":"Venetis","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"7957","key":"10.1016\/j.clgc.2026.102651_bib0009","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.clgc.2026.102651_bib0010","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14737140.2025.2512036","article-title":"The use of ctDNA for muscle-invasive bladder cancer before and after radical cystectomy","volume":"25","author":"Manolitsis","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54847-1","article-title":"AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients","volume":"15","author":"Knutson","year":"2024","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.clgc.2026.102651_bib0012","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clinical Cancer Res"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0013","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13046-025-03356-0","article-title":"Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer","volume":"44","author":"N\u00f8rgaard","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-24-1658","article-title":"Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in lethal prostate cancer","volume":"31","author":"Chauhan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.clgc.2026.102651_bib0016","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/pros.24618","article-title":"Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer","volume":"83","author":"Tripathi","year":"2023","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.beem.2015.04.005","article-title":"Androgen insensitivity syndrome","volume":"29","author":"Mongan","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.clgc.2026.102651_bib0018","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0019","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2026.102651_bib0020","article-title":"Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer","volume":"13","author":"Dincman","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0021","article-title":"Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer","volume":"12","author":"Tan","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0022","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02298-0","article-title":"Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer","volume":"20","author":"Mak","year":"2022","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.clgc.2026.102651_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092219","article-title":"Baseline plasma tumor DNA (ctDNA) correlates with psa kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide","volume":"14","author":"Conteduca","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2021.07.012","article-title":"Analysis of the prognostic significance of circulating tumor DNA in metastatic castrate resistant prostate cancer","volume":"19","author":"Shaya","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102651_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103625","article-title":"Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase","volume":"72","author":"Lin","year":"2021","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.clgc.2026.102651_bib0026","doi-asserted-by":"crossref","first-page":"905","DOI":"10.6004\/jnccn.2020.7663","article-title":"Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer: a multicenter, real-world study","volume":"19","author":"Dong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.clgc.2026.102651_bib0027","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-020-00309-w","article-title":"Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide","volume":"24","author":"Del Re","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0028","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1172\/JCI130887","article-title":"Genome-wide plasma DNA methylation features of metastatic prostate cancer","volume":"130","author":"Wu","year":"2020","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.clgc.2026.102651_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082139","article-title":"Multiplex digital PCR to detect amplifications of specific androgen receptor loci in cell-free DNA for prognosis of metastatic castration-resistant prostate cancer","volume":"12","author":"Du","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102651_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clgc.2026.102651_bib0031","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/PO.20.00047","article-title":"Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer","volume":"4","author":"Dang","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clgc.2026.102651_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00227","article-title":"Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer","volume":"3","author":"Torquato","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0033","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer","volume":"25","author":"De Laere","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102651_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00302","article-title":"Multimodal approach to outcome prediction in metastatic castration-resistant prostate cancer by integrating functional imaging and plasma DNA analysis","volume":"3","author":"Conteduca","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102651_bib0035","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/cncr.31959","article-title":"Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer","volume":"125","author":"Sonpavde","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102651_bib0036","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41391-018-0043-z","article-title":"Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients","volume":"21","author":"Kohli","year":"2018","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"7","key":"10.1016\/j.clgc.2026.102651_bib0037","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0038","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15928-y","article-title":"Circulating androgen receptor combined with 18F-fluorocholine PET\/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer","volume":"7","author":"Conteduca","year":"2017","journal-title":"Sci Rep"},{"issue":"25","key":"10.1016\/j.clgc.2026.102651_bib0039","doi-asserted-by":"crossref","first-page":"37839","DOI":"10.18632\/oncotarget.9341","article-title":"Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer","volume":"7","author":"Salvi","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0040","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.euf.2017.01.004","article-title":"Prognostic value of androgen receptor splice variant 7 in the treatment of castration-resistant prostate cancer with next generation androgen receptor signal inhibition: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0041","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.euo.2024.05.003","article-title":"Circulating biomarkers predictive of treatment response in patients with hormone-sensitive or castration-resistant metastatic prostate cancer: a systematic review","volume":"7","author":"Baboudjian","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0042","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1373\/clinchem.2008.113035","article-title":"PCR-based methods for the enrichment of minority alleles and mutations","volume":"55","author":"Milbury","year":"2009","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0043","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2353\/jmoldx.2008.080027","article-title":"Keeping up with the next generation: massively parallel sequencing in clinical diagnostics","volume":"10","author":"ten Bosch","year":"2008","journal-title":"J Mol Diagn"},{"issue":"7782","key":"10.1016\/j.clgc.2026.102651_bib0044","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"7834","key":"10.1016\/j.clgc.2026.102651_bib0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2026.102651_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216047","article-title":"Early development of esophageal squamous cell cancer: stem cells, cellular origins and early clone evolution","volume":"555","author":"Liao","year":"2023","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.clgc.2026.102651_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115699","article-title":"Fitness and transcriptional plasticity of human breast cancer single-cell-derived clones","volume":"44","author":"Nguyen","year":"2025","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0048","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009140","article-title":"Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction","volume":"13","author":"Bernatowicz","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0049","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","article-title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","volume":"28","author":"Vidal","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0050","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ijc.33362","article-title":"Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer","volume":"148","author":"Tian","year":"2021","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0051","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","article-title":"Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer","volume":"79","author":"Casanova-Salas","year":"2021","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102651_bib0052","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clgc.2026.102651_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215994","article-title":"UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways","volume":"553","author":"Lacombe","year":"2023","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.clgc.2026.102651_bib0054","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.7150\/ijbs.109271","article-title":"VAV2 exists in extrachromosomal circular DNA and contributes Enzalutamide resistance of prostate cancer via stabilization of AR\/ARv7","volume":"21","author":"Wang","year":"2025","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10424-7","article-title":"ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration","volume":"22","author":"Cui","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2026.102651_bib0056","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clgc.2026.102651_bib0057","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.eururo.2021.10.029","article-title":"Leveraging real world genomic data to advance prostate cancer precision oncology","volume":"81","author":"Beltran","year":"2022","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102651_bib0058","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1593\/neo.08582","article-title":"Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer: a pilot study","volume":"10","author":"El Sheikh","year":"2008","journal-title":"Neoplasia"},{"issue":"18","key":"10.1016\/j.clgc.2026.102651_bib0059","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-18-0653","article-title":"TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer","volume":"24","author":"Blee","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:17:19Z","timestamp":1793765839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001515"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102651","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Androgen Receptor (AR) Gene Alterations Detected in Circulating Tumor DNA (ctDNA) in Patients With Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102651","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102651"}}